KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)

Vir Biotechnology (VIR) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $636.6 million as the latest value for Q3 2019.

  • Quarterly Preferred Stock Liabilities rose 105.93% to $636.6 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $636.6 million through Sep 2019, up 105.93% year-over-year, with the annual reading at $309.1 million for FY2018, 5.68% up from the prior year.
  • Preferred Stock Liabilities hit $636.6 million in Q3 2019 for Vir Biotechnology, roughly flat from $636.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $636.6 million in Q2 2019 to a low of $307.2 million in Q2 2018.